OXiGENE Announces First Quarter Financial Results Conference Call and Webcast
April 20, 2015 16:15 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced...
OXiGENE Announces Participation in Upcoming Investor and Medical Conferences
April 02, 2015 16:15 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 2, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced...
OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering
March 20, 2015 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 20, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced...
OXiGENE Reports Financial Results for 2014
March 17, 2015 16:05 ET
|
Mateon Therapeutics
- Strong Year-End Cash Balance of $30 Million -
- Significant R&D Milestones Anticipated in 2015 -
SOUTH SAN FRANCISCO, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc....
OXiGENE Announces 2014 Financial Results Conference Call and Webcast
March 04, 2015 16:15 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report...
OXiGENE Announces Presentation and Webcast at the 27th Annual ROTH Conference on March 11th
February 24, 2015 09:15 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, announced that Dai Chaplin,...
OXiGENE Announces Presentation and Webcast at the 17th Annual BIO CEO & Investor Conference on February 10th
January 26, 2015 16:15 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, announced that David...
OXiGENE Announces Preclinical Poster Presentation on OXi4503 at Upcoming American Society of Hematology Meeting
November 20, 2014 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that a poster presentation...
OXiGENE Announces Issuance of European Patent for OXi4503 in Acute Myeloid Leukemia and other Myeloid Malignancies
November 17, 2014 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the company has been...
OXiGENE Reports Third Quarter 2014 Financial Results
November 12, 2014 16:00 ET
|
Mateon Therapeutics
- Positive Data from the Phase 2 GOG 186I Study in Ovarian Cancer Presented at Major Conference -
- Two Phase 2 Fosbretabulin Studies Initiated in Ovarian and Gastrointestinal Neuroendocrine...